Eli Lilly 'Deserves' Stock Upside: Analyst
Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
Share
Why It Matters
Eli Lilly made more money than expected from new popular medicines. Experts think the company will keep growing, so they raised their target prices.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.